{"entity":{"id":"nct05949619","kind":"trial","name":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of BL-M02D1 in non-small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors is a phase 1/2 interventional study registered as NCT05949619 by Sichuan Baili Pharmaceutical Co., Ltd., with 14 participants enrolled, started 2023-09-04 and due to reach its primary completion in 2025-12. Interventions recorded: BL-M02D1.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05949619","url":"https://clinicaltrials.gov/study/NCT05949619"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05949619","phase":"1/2","setting":"A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M02D1 for Injection in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Non-small Cell Lung Cancer","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":14,"outcomes":[]},"route":"/trials/nct05949619/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}